Advertisement

A Preliminary Report of a Controlled Study of Thymosin Alpha-1 in the Woodchuck Model of Hepadnavirus Infection

  • John L. Gerin
  • Brent E. Korba
  • Paul J. Cote
  • Bud C. Tennant
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 312)

Abstract

Thymosin alpha-1 (TA1) is one of a family of peptides with immunoregulatory activities which occur naturally in thymic tissues (1). TA1 is an acidic 28 amino acid molecule that is biologically active in a number of in vitro and in vivo assays; it is highly conserved among mammalian species and is available as a chemically-defined synthetic preparation. Detectable levels of TA1 are found in the serum of normal individuals (2). Due to the immunoregulatory properties of thymic peptides, there is current interest in their possible use in the treatment of chronic diseases, including Type B hepatitis (3). In a preliminary report, Mutchnick, et al. (4) described the possible efficacy of thymosin fraction 5 and TA1 in the treatment of patients with chronic active hepatitis due to hepatitis B virus (HBV). The purpose of the current study was to evaluate TA1 in an animal model system of HBV infection and disease.

Keywords

Chronic Active Hepatitis Amino Acid Molecule Woodchuck Hepatitis Virus Immunoregulatory Activity Thymic Peptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Goldstein, A.L., Low, T.L.K., McAdoo, M., et al., Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypeptide, Proc. Natl. Acad. Sci. USA 74:725–729 (1977).CrossRefPubMedGoogle Scholar
  2. 2.
    McClure, J.E., Lameris, N., Wara, D.W., and Goldstein, A.L., Immunochemical studies on thymosin: radioimmunoassay of thymosin alpha-1, J. Immunol. 128:368–375 (1982).PubMedGoogle Scholar
  3. 3.
    Eichberg, J.W., Seeff, L.B., Lawlor, D.L., Buskell-Bales, Z., Ishak, K., Hoofnagle, J.H., Goldstein, A.L., and Langloss, J.M., Effect of thymosin immunostimulation with and without corticosteroid immunosuppression on chimpanzee hepatitis B carriers, J. Med. Virol. 21:25–37 (1987).CrossRefPubMedGoogle Scholar
  4. 4.
    Mutchnick, M.G., Lee, H.H., Haynes, G.D., Hoffnagle, J.H., and Appelman, H.O., Thymosin treatment of chronic active hepatitis B (CAHB): a preliminary report on a controlled double blind study, Hepatology 8:1270 (1988).Google Scholar
  5. 5.
    Gerin, J.L., Cote, P.J., Korba, B.E., and Tennant, B.C., Hepadnavirus-induced liver cancer in woodchucks, Cancer Detection and Prevention 14:227–229 (1989).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • John L. Gerin
    • 1
  • Brent E. Korba
    • 1
  • Paul J. Cote
    • 1
  • Bud C. Tennant
    • 2
  1. 1.Division of Molecular Virology and Immunology Department of MicrobiologyGeorgetown UniversityRockvilleUSA
  2. 2.Department of Clinical Sciences College of Veterinary MedicineCornell UniversityIthacaUSA

Personalised recommendations